Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics Stock Surges After Drug Trial Update
03:19pm, Wednesday, 03'rd Jun 2026
Shares of TG Therapeutics Inc (NASDAQ:TGTX) are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Her
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
07:30am, Wednesday, 03'rd Jun 2026
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
07:30am, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold
Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evi
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook
01:35pm, Thursday, 28'th May 2026
TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions. The company raised 2026 BRIUMVI sales guidance to $885–$900 million, reflecting 63% year-over-
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
11:35am, Thursday, 28'th May 2026
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
08:07am, Thursday, 28'th May 2026
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:30am, Thursday, 28'th May 2026
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jeffe
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
07:30am, Wednesday, 27'th May 2026
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
07:30am, Tuesday, 26'th May 2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with re
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
11:56am, Wednesday, 20'th May 2026
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
Historic Signal Says This Biotech Outperforms
02:00pm, Monday, 11'th May 2026
TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1.2% at $42.35, after last week being rejected by the overhead $44 ceiling.
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
01:11pm, Thursday, 07'th May 2026
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
01:11pm, Wednesday, 06'th May 2026
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
09:25am, Wednesday, 06'th May 2026
TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.03 per share a year ago.
